{"title":"免疫检查点抑制剂治疗外阴和阴道黑色素瘤的单机构经验。","authors":"Amrita Ladwa, Omar Elghawy, Varinder Kaur","doi":"10.1155/2024/7327692","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to report clinical outcomes of patients with vaginal melanoma (VaM) or vulvar melanoma (VuM) who were treated with immune checkpoint inhibitors (ICI) and discuss the development of immune-related adverse events (irAE).</p><p><strong>Materials and methods: </strong>This is a retrospective case series of patients diagnosed with VaM or VuM between July 2011 and September 2022 at the University of Virginia, Emily Couric Clinical Cancer Center. Patient demographics, disease characteristics, treatment outcomes, and adverse events were abstracted. The primary outcome was incidence of irAE.</p><p><strong>Results: </strong>Eight patients were included in this study, four with VaM and four with VuM. Most (<i>n</i> = 6) had local or regional disease at first presentation, and 25% (<i>n</i> = 2) presented with distant metastasis. All patients received a CTLA-4 inhibitor and 75% (<i>n</i> = 6) received PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor. Most (75%, <i>n</i> = 6) patients experienced irAE. Of those who had irAE, 83% (<i>n</i> = 5) required therapy interruption or discontinuation. Most (66%, <i>n</i> = 4) underwent ICI rechallenge of which 75% (<i>n</i> = 3) experienced subsequent irAE. Of all patients in the series, 75% of patients (<i>n</i> = 6) had partial or complete response to ICI.</p><p><strong>Conclusion: </strong>This series is the first to detail incidence of irAEs and ICI rechallenges in vulvovaginal melanoma. Our findings indicate that while ICIs are effective, their use is associated with significant irAE development. Rechallenge of ICI after irAE is feasible but associated with risk of recurrent/new irAE. Further studies are needed to better quantify this risk.</p>","PeriodicalId":19439,"journal":{"name":"Obstetrics and Gynecology International","volume":"2024 ","pages":"7327692"},"PeriodicalIF":1.6000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335409/pdf/","citationCount":"0","resultStr":"{\"title\":\"Single Institution Experience with Immune Checkpoint Inhibitors in Vulvar and Vaginal Melanomas.\",\"authors\":\"Amrita Ladwa, Omar Elghawy, Varinder Kaur\",\"doi\":\"10.1155/2024/7327692\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aimed to report clinical outcomes of patients with vaginal melanoma (VaM) or vulvar melanoma (VuM) who were treated with immune checkpoint inhibitors (ICI) and discuss the development of immune-related adverse events (irAE).</p><p><strong>Materials and methods: </strong>This is a retrospective case series of patients diagnosed with VaM or VuM between July 2011 and September 2022 at the University of Virginia, Emily Couric Clinical Cancer Center. Patient demographics, disease characteristics, treatment outcomes, and adverse events were abstracted. The primary outcome was incidence of irAE.</p><p><strong>Results: </strong>Eight patients were included in this study, four with VaM and four with VuM. Most (<i>n</i> = 6) had local or regional disease at first presentation, and 25% (<i>n</i> = 2) presented with distant metastasis. All patients received a CTLA-4 inhibitor and 75% (<i>n</i> = 6) received PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor. Most (75%, <i>n</i> = 6) patients experienced irAE. Of those who had irAE, 83% (<i>n</i> = 5) required therapy interruption or discontinuation. Most (66%, <i>n</i> = 4) underwent ICI rechallenge of which 75% (<i>n</i> = 3) experienced subsequent irAE. Of all patients in the series, 75% of patients (<i>n</i> = 6) had partial or complete response to ICI.</p><p><strong>Conclusion: </strong>This series is the first to detail incidence of irAEs and ICI rechallenges in vulvovaginal melanoma. Our findings indicate that while ICIs are effective, their use is associated with significant irAE development. Rechallenge of ICI after irAE is feasible but associated with risk of recurrent/new irAE. Further studies are needed to better quantify this risk.</p>\",\"PeriodicalId\":19439,\"journal\":{\"name\":\"Obstetrics and Gynecology International\",\"volume\":\"2024 \",\"pages\":\"7327692\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335409/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrics and Gynecology International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/7327692\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics and Gynecology International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/7327692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Single Institution Experience with Immune Checkpoint Inhibitors in Vulvar and Vaginal Melanomas.
Objectives: This study aimed to report clinical outcomes of patients with vaginal melanoma (VaM) or vulvar melanoma (VuM) who were treated with immune checkpoint inhibitors (ICI) and discuss the development of immune-related adverse events (irAE).
Materials and methods: This is a retrospective case series of patients diagnosed with VaM or VuM between July 2011 and September 2022 at the University of Virginia, Emily Couric Clinical Cancer Center. Patient demographics, disease characteristics, treatment outcomes, and adverse events were abstracted. The primary outcome was incidence of irAE.
Results: Eight patients were included in this study, four with VaM and four with VuM. Most (n = 6) had local or regional disease at first presentation, and 25% (n = 2) presented with distant metastasis. All patients received a CTLA-4 inhibitor and 75% (n = 6) received PD-1 inhibitor alone or in combination with a CTLA-4 inhibitor. Most (75%, n = 6) patients experienced irAE. Of those who had irAE, 83% (n = 5) required therapy interruption or discontinuation. Most (66%, n = 4) underwent ICI rechallenge of which 75% (n = 3) experienced subsequent irAE. Of all patients in the series, 75% of patients (n = 6) had partial or complete response to ICI.
Conclusion: This series is the first to detail incidence of irAEs and ICI rechallenges in vulvovaginal melanoma. Our findings indicate that while ICIs are effective, their use is associated with significant irAE development. Rechallenge of ICI after irAE is feasible but associated with risk of recurrent/new irAE. Further studies are needed to better quantify this risk.
期刊介绍:
Obstetrics and Gynecology International is a peer-reviewed, Open Access journal that aims to provide a forum for scientists and clinical professionals working in obstetrics and gynecology. The journal publishes original research articles, review articles, and clinical studies related to obstetrics, maternal-fetal medicine, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine and infertility, reproductive endocrinology, and sexual medicine.